GleamWall
中文EN

PYXS Pyxis Oncology, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1782223 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-4.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin97.1%
Operating margin-554.1%
Net margin-478.9%
FCF margin-358.7%
EBITDA margin-535.6%

Returns

ROE-62.8%
ROA-46.7%
ROIC (approx.)-65.0%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets23.2%
Debt / equity0.00x
Current ratio7.49x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$11.04M$0$2.82M—$0
Cost of revenue———————$0
Gross profit———————$0
R&D expense$16.56M$16.06M$19.98M$21.71M$17.81M$17.13M$17.04M$14.02M
SG&A expense$3.97M$9.93M$4.38M$5.23M$5.65M$5.44M$5.87M$5.08M
Operating income-$20.52M-$25.99M-$24.36M-$18.30M-$23.46M-$19.75M-$22.91M-$40.07M
Pretax income-$19.98M-$25.35M—-$17.00M-$22.00M-$18.07M—-$37.73M
Income tax$0$0—$1.10M$0$283,000——
Net income-$19.98M-$25.35M-$23.27M-$18.11M-$22.00M-$18.35M-$21.16M-$35.57M
EBITDA-$20.22M-$25.69M-$23.90M-$15.40M-$22.93M-$19.21M-$22.36M-$39.52M
EPS (basic)-0.24-0.40-0.37—-0.35-0.30-0.35—
EPS (diluted)-0.24-0.40-0.37—-0.35-0.30-0.35—
Weighted avg. shares (diluted)83.51M63.99M63.47M—62.56M61.92M61.05M—
Balance sheet
Cash & equivalents$3.86M$18.86M$5.77M$15.42M$8.92M$10.73M$12.76M$19.47M
Short-term investments$51.72M$14.14M$35.25M$51.44M$67.34M$78.21M$92.67M$107.46M
Receivables—————$3.00M——
Current assets$59.13M$36.73M$45.57M$72.11M$83.07M$99.96M$111.87M$132.44M
PP&E, net$6.94M$7.24M$7.54M$8.00M$8.46M$8.92M$9.40M$9.90M
Intangibles———$0$2.43M$2.49M$2.54M$2.60M
Total assets$76.77M$54.92M$64.30M$91.52M$105.60M$123.22M$135.87M$157.18M
Current liabilities$19.94M$27.47M$16.53M$21.13M$19.38M$17.68M$14.43M$17.68M
Total liabilities$35.45M$43.48M$33.03M$38.11M$36.83M$35.57M$32.76M$36.43M
Shareholders' equity$41.32M$11.44M$31.27M$53.41M$68.78M$87.64M$103.10M$120.75M
Shares outstanding83.51M63.43M62.83M62.69M62.15M62.02M61.63M59.97M
Cash flow statement
Operating cash flow-$16.29M-$18.21M-$26.00M-$10.43M-$13.28M-$17.26M-$22.54M-$19.29M
Capital expenditure———$0———$0
Free cash flow———-$10.43M———-$19.29M
Investing cash flow-$37.29M$21.30M$16.37M$16.26M$11.47M$15.30M$15.82M$26.66M
Financing cash flow$38.59M$9.99M-$25,000$669,000-$8,000-$67,000$0$50,000
Depreciation & amortization$299,000$301,000$459,000$2.90M$527,000$535,000$552,000$550,000
Stock-based compensation$1.33M$5.53M$1.21M$2.08M$3.07M$3.02M$3.63M$2.77M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.